Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

Afsar Ali Mian, Hadiqa Raees, Sujjawal Ahmad, Oliver Ottmann, El-Nasir M A Lalani

Blood (2021) 138 (Supplement 1): 4346.

https://doi.org/10.1182/blood-2021-154511

Published: 2021

Journal Articles

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Blood (2021) 138 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2021-150120

Published: 2021

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Blood (2021) 138 (Supplement 1): 244.

https://doi.org/10.1182/blood-2021-146039

Published: 2021

Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137307

Published: 2020

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136855

Published: 2020

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

https://doi.org/10.1182/blood-2019-128178

Published: 2019

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy

Inga Nagel, Marius Bartels, Johannes Duell, Hans-Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver Ottmann, Heike Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz-August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann

Blood (2017) 130 (18): 2027–2031.

https://doi.org/10.1182/blood-2017-05-782888

Published: 2017

Includes: Supplemental data

Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 2862.

https://doi.org/10.1182/blood.V126.23.2862.2862

Published: 2015

Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 92.

https://doi.org/10.1182/blood.V126.23.92.92

Published: 2015

Journal Articles

Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

Verena Boehm, PhD, Annett Lebenatus, Marius Bartels, Inga Nagel, PhD, Heiko Trautmann, PhD, Nicola Gökbuget, MD, Dieter Hoelzer, MD, Heike Pfeifer, MD, Reiner Siebert, MD, Michael Kneba, MD, Oliver Ottmann, MD, Monika Brüggemann, MD

Blood (2013) 122 (21): 1327.

https://doi.org/10.1182/blood.V122.21.1327.1327

Published: 2013

Journal Articles

Frequency and prognostic impact of mutations in SRSF2 , U2AF1 , and ZRSR2 in patients with myelodysplastic syndromes

Felicitas Thol, Sofia Kade, Carola Schlarmann, Patrick Löffeld, Michael Morgan, Jürgen Krauter, Marcin W. Wlodarski, Britta Kölking, Martin Wichmann, Kerstin Görlich, Gudrun Göhring, Gesine Bug, Oliver Ottmann, Charlotte M. Niemeyer, Wolf-Karsten Hofmann, Brigitte Schlegelberger, Arnold Ganser, Michael Heuser

Blood (2012) 119 (15): 3578–3584.

https://doi.org/10.1182/blood-2011-12-399337

Published: 2012

Includes: Supplemental data

Journal Articles

Targeting the 5-Lipoxygenase as a Novel Principle of Stem Cell Therapy In Acute Myeloid Leukemia

Jessica Roos, Astrid Fischer, Dieter Steinhilber, Hubert Serve, Oliver Ottmann, Thorsten Maier, Martin Ruthardt

Blood (2010) 116 (21): 1846.

https://doi.org/10.1182/blood.V116.21.1846.1846

Published: 2010

Journal Articles

The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL

Afsar Mian, Anna Metodieva, Yousef Najajreh, Hubert Serve, Oliver Ottmann, Jamal Mahajna, Martin Ruthardt

Blood (2010) 116 (21): 598.

https://doi.org/10.1182/blood.V116.21.598.598

Published: 2010

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

Blood (2009) 114 (22): 912.

https://doi.org/10.1182/blood.V114.22.912.912

Published: 2009

NARROW

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

Frequency and prognostic impact of mutations in SRSF2 , U2AF1 , and ZRSR2 in patients with myelodysplastic syndromes

Targeting the 5-Lipoxygenase as a Novel Principle of Stem Cell Therapy In Acute Myeloid Leukemia

The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only